Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: Results of EUROCARE-5, a population-based study

Milena Sant, Pamela Minicozzi, Morgane Mounier, Lesley A. Anderson, Hermann Brenner, Bernd Holleczek, Rafael Marcos-Gragera, Marc Maynadié, Alain Monnereau, Gemma Osca-Gelis, Otto Visser, Roberta De Angelis

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Background: More effective treatments have become available for haematological malignancies from the early 2000s, but few large-scale population-based studies have investigated their effect on survival. Using EUROCARE data, and HAEMACARE morphological groupings, we aimed to estimate time trends in population-based survival for 11 lymphoid and myeloid malignancies in 20 European countries, by region and age. Methods: In this retrospective observational study, we included patients (aged 15 years and older) diagnosed with haematological malignancies, diagnosed up to Dec 31, 2007, and followed up to Dec 31, 2008. We used data from the 30 cancer registries (across 20 countries) that provided continuous incidence and good quality data from 1992 to 2007. We used a hybrid approach to estimate age-standardised and age-specific 5-year relative survival, for each malignancy, overall and for five regions (UK, and northern, central, southern, and eastern Europe), and four 3-year periods (1997-99, 2000-02, 2003-05, 2006-08). For each malignancy, we also estimated the relative excess risk of death during the 5 years after diagnosis, by period, age, and region. Findings: We analysed 560 444 cases. From 1997-99 to 2006-08 survival increased for most malignancies: the largest increases were for diffuse large B-cell lymphoma (42·0% [95% CI 40·7-43·4] to 55·4% [54·6-56·2], p

Original languageEnglish
Pages (from-to)931-942
Number of pages12
JournalThe Lancet Oncology
Volume15
Issue number9
DOIs
Publication statusPublished - 2014

Fingerprint

Hematologic Neoplasms
Survival
Population
Neoplasms
Eastern Europe
Lymphoma, Large B-Cell, Diffuse
Observational Studies
Registries
Retrospective Studies
Incidence

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Survival for haematological malignancies in Europe between 1997 and 2008 by region and age : Results of EUROCARE-5, a population-based study. / Sant, Milena; Minicozzi, Pamela; Mounier, Morgane; Anderson, Lesley A.; Brenner, Hermann; Holleczek, Bernd; Marcos-Gragera, Rafael; Maynadié, Marc; Monnereau, Alain; Osca-Gelis, Gemma; Visser, Otto; De Angelis, Roberta.

In: The Lancet Oncology, Vol. 15, No. 9, 2014, p. 931-942.

Research output: Contribution to journalArticle

Sant, M, Minicozzi, P, Mounier, M, Anderson, LA, Brenner, H, Holleczek, B, Marcos-Gragera, R, Maynadié, M, Monnereau, A, Osca-Gelis, G, Visser, O & De Angelis, R 2014, 'Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: Results of EUROCARE-5, a population-based study', The Lancet Oncology, vol. 15, no. 9, pp. 931-942. https://doi.org/10.1016/S1470-2045(14)70282-7
Sant, Milena ; Minicozzi, Pamela ; Mounier, Morgane ; Anderson, Lesley A. ; Brenner, Hermann ; Holleczek, Bernd ; Marcos-Gragera, Rafael ; Maynadié, Marc ; Monnereau, Alain ; Osca-Gelis, Gemma ; Visser, Otto ; De Angelis, Roberta. / Survival for haematological malignancies in Europe between 1997 and 2008 by region and age : Results of EUROCARE-5, a population-based study. In: The Lancet Oncology. 2014 ; Vol. 15, No. 9. pp. 931-942.
@article{5fde034c0c554aa285672a7f3805fcee,
title = "Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: Results of EUROCARE-5, a population-based study",
abstract = "Background: More effective treatments have become available for haematological malignancies from the early 2000s, but few large-scale population-based studies have investigated their effect on survival. Using EUROCARE data, and HAEMACARE morphological groupings, we aimed to estimate time trends in population-based survival for 11 lymphoid and myeloid malignancies in 20 European countries, by region and age. Methods: In this retrospective observational study, we included patients (aged 15 years and older) diagnosed with haematological malignancies, diagnosed up to Dec 31, 2007, and followed up to Dec 31, 2008. We used data from the 30 cancer registries (across 20 countries) that provided continuous incidence and good quality data from 1992 to 2007. We used a hybrid approach to estimate age-standardised and age-specific 5-year relative survival, for each malignancy, overall and for five regions (UK, and northern, central, southern, and eastern Europe), and four 3-year periods (1997-99, 2000-02, 2003-05, 2006-08). For each malignancy, we also estimated the relative excess risk of death during the 5 years after diagnosis, by period, age, and region. Findings: We analysed 560 444 cases. From 1997-99 to 2006-08 survival increased for most malignancies: the largest increases were for diffuse large B-cell lymphoma (42·0{\%} [95{\%} CI 40·7-43·4] to 55·4{\%} [54·6-56·2], p",
author = "Milena Sant and Pamela Minicozzi and Morgane Mounier and Anderson, {Lesley A.} and Hermann Brenner and Bernd Holleczek and Rafael Marcos-Gragera and Marc Maynadi{\'e} and Alain Monnereau and Gemma Osca-Gelis and Otto Visser and {De Angelis}, Roberta",
year = "2014",
doi = "10.1016/S1470-2045(14)70282-7",
language = "English",
volume = "15",
pages = "931--942",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "9",

}

TY - JOUR

T1 - Survival for haematological malignancies in Europe between 1997 and 2008 by region and age

T2 - Results of EUROCARE-5, a population-based study

AU - Sant, Milena

AU - Minicozzi, Pamela

AU - Mounier, Morgane

AU - Anderson, Lesley A.

AU - Brenner, Hermann

AU - Holleczek, Bernd

AU - Marcos-Gragera, Rafael

AU - Maynadié, Marc

AU - Monnereau, Alain

AU - Osca-Gelis, Gemma

AU - Visser, Otto

AU - De Angelis, Roberta

PY - 2014

Y1 - 2014

N2 - Background: More effective treatments have become available for haematological malignancies from the early 2000s, but few large-scale population-based studies have investigated their effect on survival. Using EUROCARE data, and HAEMACARE morphological groupings, we aimed to estimate time trends in population-based survival for 11 lymphoid and myeloid malignancies in 20 European countries, by region and age. Methods: In this retrospective observational study, we included patients (aged 15 years and older) diagnosed with haematological malignancies, diagnosed up to Dec 31, 2007, and followed up to Dec 31, 2008. We used data from the 30 cancer registries (across 20 countries) that provided continuous incidence and good quality data from 1992 to 2007. We used a hybrid approach to estimate age-standardised and age-specific 5-year relative survival, for each malignancy, overall and for five regions (UK, and northern, central, southern, and eastern Europe), and four 3-year periods (1997-99, 2000-02, 2003-05, 2006-08). For each malignancy, we also estimated the relative excess risk of death during the 5 years after diagnosis, by period, age, and region. Findings: We analysed 560 444 cases. From 1997-99 to 2006-08 survival increased for most malignancies: the largest increases were for diffuse large B-cell lymphoma (42·0% [95% CI 40·7-43·4] to 55·4% [54·6-56·2], p

AB - Background: More effective treatments have become available for haematological malignancies from the early 2000s, but few large-scale population-based studies have investigated their effect on survival. Using EUROCARE data, and HAEMACARE morphological groupings, we aimed to estimate time trends in population-based survival for 11 lymphoid and myeloid malignancies in 20 European countries, by region and age. Methods: In this retrospective observational study, we included patients (aged 15 years and older) diagnosed with haematological malignancies, diagnosed up to Dec 31, 2007, and followed up to Dec 31, 2008. We used data from the 30 cancer registries (across 20 countries) that provided continuous incidence and good quality data from 1992 to 2007. We used a hybrid approach to estimate age-standardised and age-specific 5-year relative survival, for each malignancy, overall and for five regions (UK, and northern, central, southern, and eastern Europe), and four 3-year periods (1997-99, 2000-02, 2003-05, 2006-08). For each malignancy, we also estimated the relative excess risk of death during the 5 years after diagnosis, by period, age, and region. Findings: We analysed 560 444 cases. From 1997-99 to 2006-08 survival increased for most malignancies: the largest increases were for diffuse large B-cell lymphoma (42·0% [95% CI 40·7-43·4] to 55·4% [54·6-56·2], p

UR - http://www.scopus.com/inward/record.url?scp=84905005458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905005458&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(14)70282-7

DO - 10.1016/S1470-2045(14)70282-7

M3 - Article

C2 - 25030467

AN - SCOPUS:84905005458

VL - 15

SP - 931

EP - 942

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 9

ER -